All In Biotech

Drug Trial Radar · NCT05043766

Evaluation of Oral PF614 Relative to OxyContin (PF614-102)

A Phase 1b, Randomized 2-Part Single-Center Study to Evaluate the PK and Safety of Multiple Ascending Oral Doses of PF614 and the Food Effect and BA/BE of Single Oral Doses of PF614 Relative to OxyContin in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Sep 8, 2021

Primary completion

Mar 21, 2022

Study completion Mar 21, 2022

Sponsor

Lead sponsor
Ensysce BiosciencesIndustry
Sponsor type
Industry
Collaborators
PRA Health Sciences
First posted
Sep 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center study incorporating 2 parts: A Multiple Ascending Dose Study (Part A) and a comparative Bioavailability/Bioequivalence and Food Effect study (Part B). Both parts of the study will be conducted in healthy adult subjects.

Conditions

  • Healthy Volunteers

Interventions

  • PF614Drug

    PF614 is an oxycodone prodrug

  • Naltrexone HydrochlorideDrug

    Naltrexone HCl tablets, 50 mg, will be used to block the opioid effects in healthy volunteers

  • OxyContinDrug

    Bioequivalence single-dose comparison to OxyContin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: 30 days
  2. Pharmacokinetics AUC [Area Under the Curve]Time frame: Full PK sampling time points will be 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
  3. Pharmacokinetics Cmax [Maximum Plasma Concentration]Time frame: PK sampling time points will be 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
  4. Pharmacokinetics Tlag [Time to first measurable plasma concentration]Time frame: PK sampling time points will be 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
  5. Pharmacokinetics Tmax [Time to maximum plasma concentration]Time frame: PK sampling time points 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
  6. Pharmacokinetics AUC, Steady StateTime frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
  7. Pharmacokinetics CL/F [Clearance]Time frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
  8. Pharmacokinetics Cmax, Steady StateTime frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
  9. Pharmacokinetics Tmax, Steady StateTime frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
  10. Pharmacokinetics t1/2 [Half-life]Time frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
  11. Pharmacokinetics Vz/F [Volume of Distribution]Time frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
  12. Pharmacokinetics elimination rateTime frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
  13. Pharmacokinetics Ctrough [Minimum Plasma Concentration before next dose]Time frame: Prior to dosing on Days 2, 3, and 4
  14. Pharmacokinetics Part B AUCTime frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
  15. Pharmacokinetics Part B AUC 0-tTime frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
  16. Pharmacokinetics Part B CmaxTime frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
  17. Bioavailability and BioequivalenceTime frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PRA Health Sciences-Early Development Services

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.